A clinical-stage in vivo gene editing company committed to pioneering the next generation of precision genetic medicines
YolTech Therapeutics is a pioneering biotechnology research company dedicated to developing the next generation of precision genetic medicines. Leveraging innovative gene editing technologies and an advanced lipid nanoparticle (LNP) delivery system, YolTech Therapeutics has created a versatile platform to address a wide range of serious diseases.
Based in Shanghai at No.58 Tanzhu Road, 12F Building A, YolTech Therapeutics is committed to developing internal capabilities, including end-to-end manufacturing, to ensure the highest standards of quality and scalability. Their pipeline covers cardiovascular, metabolic, and rare genetic diseases, with multiple programs already in the clinic, including YOLT-201 (ATTR), YOLT-101 (HeFH), YOLT-204 (TDT/SCD), and YOLT-203 (PH1).
YolTech Therapeutics is poised to revolutionize the treatment of genetic diseases through its innovative approach and dedication to excellence. YolTech Therapeutics is actively expanding its reach and impact in the biotechnology sector. We invite the management team at YolTech Therapeutics to create a customized and exclusive company showcase and product listing on our platform, to further amplify your presence and success.
Other organizations in the same industry
This company is also known as